A phase II study of cisplatin in patients with biliary tract carcinoma.
A phase II study of cisplatin was performed in 13 previously untreated patients with unresectable biliary tract carcinoma. The drug was given intravenously at a dose of 80 mg/m2/day once every 4 weeks. Of 13 patients evaluated, 1 showed partial response lasting 3 months, while no patients showed complete response. Of 9 patients, whose serum level of carcinoembryonic antigen (CEA) was high (> or = 10 ng/ml) before treatment, 4 showed > or = 50% reduction in serum CEA level after treatment. The current study indicates that cisplatin does not have significant antitumor activity against biliary tract carcinoma.
Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
S
S
Okada
H
H
Ishii
H
H
Nose
M
M
Yoshimori
T
T
Okusaka
K
K
Aoki
M
M
Iwasaki
J
J
Furuse
M
M
Yoshino
D000293:Adolescent; D000328:Adult; D000368:Aged; D001661:Biliary Tract Neoplasms / Q000188:drug therapy*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D002272:Carcinoembryonic Antigen; D002945:Cisplatin